Clinical Trial Update: Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

The document announces an ongoing Phase 1/2 trial evaluating the combination of nintedanib with an EGFR tyrosine kinase inhibitor in patients with EGFR-mutated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EGFR Tyrosine Kinase Inhibitor (EGFR tyrosine kinase inhibitor)
• Nintedanib (nintedanib)

Snippet

Sponsor: China Medical University Hospital | Conditions: Non-small Cell Lung Cancer, EGFR Gene Mutation | Phase 1, Phase 2 | Status: RECRUITING